ChromaDex (CDXC)
(Delayed Data from NSDQ)
$3.07 USD
+0.30 (10.83%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $3.07 0.00 (0.00%) 7:00 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Brokerage Reports
ChromaDex Corporation [CDXC]
Reports for Purchase
Showing records 21 - 40 ( 117 total )
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Q1 Stronger Than Expected; With Good Revenue Momentum and Cost Discipline
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Record Quarterly Revenue; Lukewarm Outlook; Adjusting PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Q4 Sales, Op. Inc. in Line; Posts First Positive Adj. Quarterly EBITDA
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
35th Annual ROTH MKM Conference - Consumer Track - March 12-14
Provider: Roth Capital Partners, Inc.
Analyst: KORANDA M
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Nicotinamide Riboside Cocktail Aids Alzheimer''s Cognition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Cash Flow Breakeven Status Possibly Imminent; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
3Q Results and 4Q Guidance Show Company on the Cusp of Positive EBITDA
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Separating Manufacturing from Design the Next Step in INTC?s Turn-a-Round
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Strengthens Balance Sheet With Additional Cash, Bolsters Entry Into China
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Revenue Miss; Revised Growth Trajectory; Lowering PT to $5.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
2Q Shows Prioritization of Path to Profitability Despite Rev Shortfall
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Asian Footprint Expansion; 1Q22 Financial Results; Modulating PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Q1 Results Largely In-Line With Estimates, Despite Headwinds
Provider: Roth Capital Partners, Inc.
Analyst: MCGOWAN S
Company: ChromaDex Corporation
Industry: Medical - Biomedical and Genetics
Product and Patent Portfolio Expansion; 2021 Financials; Lowering PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R